The Effect of Rosiglitazone on Vascular Function in Patients with Advanced Chronic Kidney Disease

Raine Medical Research foundation (pending)0 sites70 target enrollmentOctober 25, 2005

Overview

No summary available.

Registry

who.int

Start Date

October 25, 2005

End Date

TBD

Last Updated

6 years ago

Study Type

Interventional

Sex

All

Sponsor

Raine Medical Research foundation (pending)

•All patients on haemodialysis or peritoneal dialysis for Chronic kidney disease, Patients should be stable on dialysis for at least 6 months with adequate indices of dialysis (Fractional Reduction of Urea, FRU \> 0\.67 or Kt/V \> 0\.3\); All patients with moderate\-to\-severe stages 3\-5 chronic kidney disease (GFR \< 60ml/min); Patients will be selected for having the Metabolic Syndrome as defined by the WHO criteria \[31] based on our previous data showing that these patients had markedly impaired vascular function:1\. Insulin resistance identified by 1 of the following: Type 2 diabetes, impaired fasting glucose \> 6\.1 mmol/L, impaired glucose tolerance or increased fasting insulin \> 75th percentile for the population (8 mU/L).PLUS ANY 2 OF THE FOLLOWING:1\. Antihypertensive medication and/or systolic blood pressure \>\= 140mmHg or diastolic blood pressure \>\= 90 mmHg.2\. Plasma triglycerides \> 1\.7 mmol/L3\. HDL\-cholesterol \< 0\.9 mmol/L in men and \< 1\.0 mmol/L in women4\. Body mass index \> 30 kg/m2 and/or waist:hip ratio \> 0\.9 in men and 0\.85 in women5\. Urinary albumin excretion rate \>\= 20 microg/min.

•Type 1 diabetes mellitus; Nephrotic\-range proteinuria; Liver enzymes \> 2 times upper limit of normal; Alcohol consumption \> 3 standard drinks/day; Immunosuppressive therapy for renal transplantation; Cardiovascular event or unstable cardiovascular disease in preceding 6 months; Symptomatic or NYHA heart failure stage III or IV; Hb \< 110g/L; Significant psychiatric disorder; Active infection or inflammation.